Mitomycin C

  • Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer


Sodium Thiosulfate Solution Pyridoxine Hydrochloride Topical Cool Adverse Skin Reaction Advanced Gastrointestinal Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Rentschler R, Wilbur D: Pyridoxine: a potential local antidote for mitomycin-C extravasation. J Surg Oncol 37: 269–271, 1988.PubMedCrossRefGoogle Scholar
  2. [2]
    Argenta LC, Manders EK: Mitomycin C extravasation injuries. Cancer 51: 1080–1082, 1983.PubMedCrossRefGoogle Scholar
  3. [3]
    Bertelli G, Dini D, Forno G, et al: Dimethylsulphoxide and cooling after extravasation of antitumour agents. Lancet 341: 1098–1099, 1993.PubMedCrossRefGoogle Scholar
  4. [4]
    Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.PubMedGoogle Scholar
  5. [5]
    Tsavaris NB, Komitsopoulou P, Karagiaouris P, et al: Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 30: 330–333, 1992.PubMedCrossRefGoogle Scholar
  6. [6]
    Tsavaris NB, Karagiaouris P, Tzannou I, et al: Conservative approach to the treatment of chemotherapy-induced extravasation. J Dermatol Surg On-col 16: 519–522, 1990.Google Scholar
  7. [7]
    Ludwig CU, Stoll HR, Obrist R, et al: Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and a-tocopherole. Eur J Cancer Clin Oncol 23: 327–329, 1987.PubMedCrossRefGoogle Scholar
  8. [8]
    Khanna AK, Khanna A, Asthana AK, et al: Mitomycin C extravasation ulcers. J Surg Oncol 28: 108–110, 1985.PubMedCrossRefGoogle Scholar
  9. [9]
    Bowers DG, Lynch JB: Adriamycin extravasation. Plast Reconstr Surg 61: 86–92, 1978.PubMedCrossRefGoogle Scholar
  10. [10]
    Fuller B, Lind M, Bonomi P: Mitomycin C extravasation exacerbated by sunlight. Ann Intern Med 94: 542, 1981.PubMedCrossRefGoogle Scholar
  11. [11]
    Moertel CG, Reitemeier RJ, Hahn RG: Mitomycin C therapy in advanced gastrointestinal cancer. JAMA 204: 111–114, 1968.CrossRefGoogle Scholar
  12. [12]
    Alberts DS, Dorr RT: Case report: topical DMSO for mitomycin-C-induced skin ulceration. Oncol Nurs Forum 18: 693–695, 1991.PubMedGoogle Scholar
  13. [13]
    Aizawa H, Tagami H: Delayed tissue necrosis due to mitomycin C. Acta Derm Venereol 67: 364–366, 1987.PubMedGoogle Scholar
  14. [14]
    Herrera D, Burnham N: DMSO and extravasation of mitomycin. Oncol Nurs Forum 16: 155, 1989.PubMedGoogle Scholar
  15. [15]
    Wood HA, Ellerhorst-Ryan JM: Delayed adverse skin reactions associated with mitomycin-C administration. Oncol Nurs Forum 11: 14–18, 1984.PubMedGoogle Scholar
  16. [16]
    Bartkowski-Dodds L, Reville B: Extensive tissue ulceration due to apparent sensitivity reactions to mitomycin. Cancer Treat Rep 69: 925–927, 1985.PubMedGoogle Scholar

Secondary literature

  1. [17]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  2. [18]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  3. [19]
    Krämer I: Onkologische Pharmazie. In: Jaehde U, Radziwill R, Mühlebach S, et al (eds) Lehrbuch der Klinischen Pharmazie. Wissenschaftliche Verlagsgesellschaft mbH, 1st edition: 268–269, 1998.Google Scholar
  4. [20]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  5. [21]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Mitomycin: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: 35, 1997.Google Scholar
  6. [22]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.Google Scholar
  7. [23]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  8. [24]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  9. [25]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  10. [26]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar
  11. [27]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  12. [28]
    Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.Google Scholar
  13. [29]
    Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guidelines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.PubMedGoogle Scholar

Further reading

  1. [—]
    Averbuch SD, Boldt M, Gaudiano G, et al: Experimental chemotherapy-induced skin necrosis in swine. J Clin Invest 81: 142–148, 1988.PubMedCrossRefGoogle Scholar
  2. [—]
    Dorr RT, Soble MJ, Liddil JD, et al: Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dim-ethyl sulfoxide. J Clin Oncol 4: 1399–1404, 1986.PubMedGoogle Scholar
  3. [—]
    Hahn SM, Sullivan FJ, De Luca AM, et al: Protection of mitomycin C induced skin extravasation with the nitroxide, 3-carbamoyl-proxyl (3CP). Int J Oncol 10: 119–123, 1997.PubMedGoogle Scholar
  4. [—]
    Ignoffo RJ, Tomlin W, Rubinstein E, et al: A model for skin toxicity of antineoplastic drugs: doxorubicin (DOX), mitomycin-C (MMC), and vincristine (VCR). Clin Res 29: 437A, 1981.Google Scholar
  5. [—]
    Johnston-Early A, Cohen MH: Mitomycin C-induced skin ulceration remote from infusion site. Cancer Treat Rep 65: 529, 1981.PubMedGoogle Scholar
  6. [—]
    Loth TS, Eversmann WW: Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg 11A: 388–396, 1986.Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations